CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗 BCMA CAR-T 细胞治疗 1 例膜 BCMA 极高表达患者：病例报告
英文原题：Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
查看英文原题
Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
B细胞成熟抗原（BCMA）靶向CAR-T 细胞疗法是治疗复发/难治性多发性骨髓瘤（R/R MM）的一种突破性方法；然而，有必要进行优化以最大化患者获益。我们报告一例61岁女性原发性难治性MM患者，表现为膜BCMA高表达和可溶性BCMA（sBCMA）低表达，在接受抗BCMA CAR-T（CT103A）治疗后发生4级细胞因子释放综合征，并死于重症肺炎。本病例强调了评估BCMA表达范围对于接受BCMA CAR-T 治疗患者疗效和安全性的重要性。对于表现为膜BCMA极高表达和sBCMA极低表达的患者，应考虑存在-secretase相关基因突变。对此类患者还应特别注意细胞因子释放综合征的预防和治疗。
展开英文摘要原文
B cell maturation antigen (BCMA)-directed CAR-T cell therapy is a disruptive approach for treating relapsed/refractory multiple myeloma (R/R MM); however, optimization is necessary to maximize patient benefit.
We report the case of a 61-year-old woman with primary refractory MM who presented with high expression of membrane BCMA and low expression of soluble BCMA (sBCMA), experienced grade 4 cytokine release syndrome, and died fromsevere pneumonia after receiving anti-BCMA CAR-T (CT103A) therapy. This case highlights the importance of assessing the expression range of BCMA for its efficacy and safety in patients receiving BCMA CAR-T therapy.
For patients who present with extremely high membrane BCMA expression and extremely low sBCMA expression, the presence of -secretase-related gene mutations should be considered. Special attention should also be paid to the prevention and treatment of cytokine release syndrome in such patients.
论文信息
- 作者
- Li D、Que Y、Ding S、Hu G、Wang W、Mao X、Wang Y、Li C
- 第一作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
- 通讯作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China xiaomin@tjh.tjmu.edu.cn 260606299@qq.com.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Journal for immunotherapy of cancer2022 Sep
- 原文标识
- PubMed 36137648 · DOI 10.1136/jitc-2022-005403
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →